15 DNA methylation biomarkers

The term 15 DNA methylation biomarkers refers to a specific panel of epigenetic markers used primarily for diagnostic and prognostic purposes in oncology. These biomarkers consist of 15 distinct genomic regions, typically gene promoters, where the addition of methyl groups to cytosine residues (DNA methylation) serves as a signal for gene silencing or activation (PubMed: 26334364). Such panels are frequently developed to improve the early detection of cancers, such as lung adenocarcinoma or hepatocellular carcinoma, by identifying aberrant methylation patterns that occur early in the disease process (PubMed: 31431634). Unlike traditional therapeutic targets like receptors or enzymes, these biomarkers are not directly drugged to elicit a therapeutic effect; instead, they serve as indicators of the cellular state and disease progression. However, the methylation status of these biomarkers can be modulated by epigenetic therapies, such as DNA methyltransferase (DNMT) inhibitors like azacitidine and decitabine, which aim to restore normal gene expression patterns (NIH: StatPearls). In clinical practice, these 15-gene signatures are utilized to stratify patients into risk groups, predict survival outcomes, and monitor the efficacy of treatments.

Other names

15-gene DNA methylation signature15-CpG methylation panel15-gene epigenetic signature

DNA methyltransferase inhibition